MLN9708 in Relapsed Multiple Myeloma Not Refractory to Bortezomib

Clinical Pearls

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.

• 16% of patients had a pre-specified response (minimum minor response by end of Cycle 2 or partial response by end of Cycle 4)
• 35% of patients had partial response or better under the approach of receiving MLN9708 alone and adding dexamethasone if it did not work well
• The most common side effects in this trial (fatigue, drop in platelet counts, nausea, and diarrhea) were well managed

<<<

Back to the conference page